PART I: INTRODUCTION
1. "CK2, a protein kinase for all seasons" (Lorenzo A. Pinna Dept. Biological Chemistry, University of Padua, Padua, Italy.
PART II: MOLECULAR AND STRUCTURAL ASPECTS
2. "CK2 structures in the light of the spine concept of eukaryotic protein kinases " (Karsten Niefind, University of Cologne, Institute of Biochemistry, Cologne, Germany. E
3. "Structural bases for CK2 inhibition" (Roberto Battistutta, Department of Chemistry, University of Padua- Padova, Italy.
4. "The interactome of protein kinase CK2" (Mathias Montenarth, University of the Saarland, Medical Biochemistry and Molecular Biology, Homburg, Germany.
5. "The phosphoproteome generated by protein kinase CK2" (Mauro Salvi & Lorenzo A. Pinna Dept. Biological Chemistry, University of Padua, Padua, Italy.
PART III: FUNCTIONAL ASPECTS
6. "Intersection of CK2 with other signalling pathways" (David Litchfield, University of Western Ontario, Department of Biochemistry, London, Ontario, Canada.
7. "The role of protein kinase CK2 in the p53 response" (David W. Meek, University of Dundee, Biomedical Research Institute Ninewells Hospital, Dundee, UK.
8. "CK2 in embryonic development" (Isabel Dominguez, Boston University School of Medicine, Boston, MA, USA.
9. "Role of CK2 in the control of epithelial cell plasticity" (Claude Cochet, INSERM U873 iRTSV- CEA Grenoble, France.
10. "CK2 and circadian rhythm"
11. "The pivotal role of CK2 in chaperoning the kinome" (Yoshihiko Miyata, Kyoto University, Dept. Cell & Develop. Biology, Kyoto, Japan.
12. "CK2: a global regulator of cell survival" (Olaf-G. Issinger, University of Southern Denmark, Institute of Biochemistry and Molecular Biology, Odense, Denmark.
13. "Specific features of plant CK2" (Montserrat Pages, CSIC, CRAG, Barcelona, Spain.
PART IV: CK2 AND NEOPLASIA
14. "The oncogenic potential of CK2" (David C. Seldin, Boston University Medical Center, Department of Medicine, Boston MA, USA.
15. "CK2 suppression of apoptosis and its implication in cancer biology and therapy" (Khalil Ahmed, University of Minnesota and V.A. Medical Center, Minneapolis, MN, USA.
16. "Abnormal levels of CK2 and the generation of cancer "addiction" (Maria Ruzzene, Dept. Biological Chemistry, University of Padua, Padua, Italy.
17. "CK2 as an ideal target in cancer therapy: combining inhibitors of CK2 with various classes of chemotherapeutic agents" (Kenna Anderes, Cylene Pharmaceuticals, Cancer Biology, San Diego, CA, USA.
18. " CK2 in normal and malignant hematopoiesis" (Francesco Piazza, Venetian Institute of Molecular Medicine - VIMM, Padova, Italy.
